ARTICLE | Company News
Concordia, Kadmon deal
January 16, 2012 8:00 AM UTC
Kadmon acquired salirasib ( KD032) from Concordia. The Ras antagonist is in Phase II testing to treat solid tumors. MTS Health Partners advised Concordia. Financial terms were not disclosed. Ono Pha...